Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of MK-3102 (Omarigliptin) vs Placebo in Type 2 Diabetes Mellitus with Moderate/Severe Chronic Kidney Disease or Dialysis
2012-002332-85Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Omarigliptin arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in A1C at Week 24. Started Jan 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002332-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002332-85.